GeneOne Life Science, Inc (011000) Fair Value & Analysis
Healthcare · KR · Market cap 83.2B KRW
Fair value as of: Jul 6, 2026
From 1 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 1,804 KRW to 302.20 KRW (−83.3%) since Jun 24, 2026. Share price −56.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 577.00 KRW – 2,900 KRW · fair‑value band 225.52 KRW – 451.05 KRW · the 577.00 KRW price screens above the 302.20 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GeneOne Life Science, Inc (011000) currently trades at 577.00 KRW, while our model-based Fair Value estimate is 302.20 KRW — implying the stock looks roughly 47.6% overvalued today. We read business quality at 18/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 17.1B KRW. Revenue declined 69.6% year over year. It earns a return on equity of -71.2%. Net debt stands at 27.9B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 225.52 KRW (bear case) to 451.05 KRW (bull case); at 577.00 KRW, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -48%, 011000 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company's nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C re-infection prophylaxis, as …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GeneOne Life Science, Inc reported revenue of 23.0B KRW in FY2025 versus 38.7B KRW in FY2021, a compound −12.2%/yr. Reported net income was −51.9B KRW in FY2025.
Is 011000 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GeneOne Life Science, Inc (011000) undervalued?
What is the fair value of 011000?
What is the quality score of 011000?
What is the revenue of GeneOne Life Science, Inc (011000)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.